Evidence map›Paper›PMID 42361799›Full record

ArticleCell systems2026

Deciphering protein mutation-phenotype linkages from CRISPR-based tiling mutagenesis screens.

Wei He, Jen-Wei Huang, Yalong Wang, Samuel B Hayward, Giuseppe Leuzzi, Rongjie Fu, Shuyue Wang, Alina Vaitsiankova, Yiwen Chen, Mark T Bedford and 3 more

Abstract read
In one paragraph

Article in Cell systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wei HeDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Jen-Wei HuangDepartment of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Yalong WangDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Samuel B HaywardDepartment of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Giuseppe LeuzziDepartment of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Rongjie FuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Shuyue WangDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Alina VaitsiankovaDepartment of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Yiwen ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Raphael GueroisInstitute for Integrative Biology of the Cell (I2BC), University of Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, France. Electronic address: raphael.guerois@cea.fr.
Alberto CicciaDepartment of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA; Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: ac3685@cumc.columbia.edu.
Han XuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: hxu4@mdanderson.org.

Funding

Replication fork remodeling and genomic stabilityR01CA197774 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alberto Ciccia · 2016 to 2026
$4.2M
Computational approaches for protein functional analysis using CRISPR screensR35GM137927 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI XU, HAN · 2020 to 2024
$2.0M
A Functional Analysis of Arginine MethylationR35GM153387 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD · 2024 to 2026
$1.2M
Computational and experimental approaches for decoding the function and regulation of unconventional RNA translationR35GM156417 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yiwen Chen · 2025 to 2026
$899k
NCI NIH HHS R01 CA197774NIGMS NIH HHS R35 GM137927NIGMS NIH HHS R35 GM153387NIGMS NIH HHS R35 GM156417
6 · The paper itself

Abstract

CRISPR-based high-throughput mutagenesis screens enable systematic mapping of mutations to phenotypes, yet deciphering mutation-phenotype links remains challenging. Here, we present ProTiler-Mut, a versatile computational framework that leverages tiling mutagenesis screens, which introduce variants across entire protein sequences, to analyze mutation effects at the levels of residues, substructures, and protein-protein interactions (PPIs). Applying ProTiler-Mut to multi-condition base-editing (BE) screens targeting DNA damage response proteins and T cell regulators, we define a separation-of-function (SoF) category beyond the conventional loss-of-function (LoF) and gain-of-function (GoF) classes, where SoF mutations show the strongest enrichment for ClinVar-annotated pathogenic variants. ProTiler-Mut also identifies candidate substructures that enable functional inference of unscreened pathogenic mutations and prioritizes candidate phenotype-associated PPIs potentially disrupted by functional variants. Using ProTiler-Mut, in cells with elevated programmed cell death 1 (PD-1) expression, we identify pathogenic GoF mutations that constitute a substructure that may disrupt mitogen-activated protein kinase (MAPK)1-RSK1 interactions and lead to MAPK activation. Finally, we show that ProTiler-Mut is applicable across different mutagenesis screening platforms. A record of this paper's transparent peer review process is included in the supplemental information.

Indexed as

MutagenesisClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsHumansMutationPhenotypecomputational methodCRISPRmutation-phenotypeProTiler-Muttiling mutagenesis screen

Identifiers

PMID42361799
PMCPMC13463601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.